Monozyme India Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 3.12 Cr
as on 10-12-2024
- Company Age 35 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.59 Cr
as on 10-12-2024
- Satisfied Charges ₹ 12.21 Cr
as on 10-12-2024
- Revenue -37.50%
(FY 2023)
- Profit 5.15%
(FY 2023)
- Ebitda 21.38%
(FY 2023)
- Net Worth -0.55%
(FY 2023)
- Total Assets -0.35%
(FY 2023)
About Monozyme India
The Corporate was formerly known as Monozyme India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.12 Cr.
The company currently has active open charges totaling ₹7.59 Cr. The company has closed loans amounting to ₹12.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anand Maloo, Rabindra Walia, Bijinder Rattan, and Two other members serve as directors at the Company.
- CIN/LLPIN
L24239TG1989PLC010220
- Company No.
010220
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Jul 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Monozyme India?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Maloo  | Director | 30-Oct-2004 | Current |
| Rabindra Walia | Director | 16-Feb-2008 | Current |
| Bijinder Rattan | Director | 01-Feb-2007 | Current |
| Kali Sharma | Director | 16-Feb-2008 | Current |
| Veeram Reddy | Director | 28-Feb-2005 | Current |
Financial Performance and Corporate Structure Insights of Monozyme India.
Monozyme India Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 37.5% decrease. The company also saw a slight improvement in profitability, with a 5.15% increase in profit. The company's net worth dipped by a decrease of 0.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Monozyme India?
In 2019, Monozyme India had a public holding of 100.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Commarce Creation Date: 10 Sep 2005 | ₹7.15 Cr | Open |
Technology Developmen And Inforanationcompanyof India Limite Creation Date: 29 Mar 1990 | ₹4.40 M | Open |
State Bank Of Hyderabad Creation Date: 07 Mar 2001 | ₹2.00 Cr | Satisfied |
How Many Employees Work at Monozyme India?
Unlock and access historical data on people associated with Monozyme India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Monozyme India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Monozyme India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
